BOCA RATON, Fla, March 03, 2016 -- RxStrategies, Inc. is pleased to announce the appointment of Russell Crane to the new position of Sales Manager - Northeast Region. He joins the RxStrategies’ sales team and has responsibility for sales and delivery of customized 340B pharmacy administration and split billing solutions to providers located in the Northeast Region.
"I am very pleased to welcome Russell to the RxStrategies’ team,” said Fenton Markevich, Chief Executive Officer for RxStrategies. “We look forward to incorporating Russell’s market and product expertise and knowledge for the benefit of our existing and future clients. We believe that Russell will be a strong addition and will complement our current market facing sales and account management teams.”
Russell joins RxStrategies with strong pharmacy industry background, with a particularly strong presence in the Northeast in market facing roles to the pharmacy administration and 340B markets. Russell is a graduate of Northeastern University.
"RxStrategies has a strong reputation in the marketplace with both a unique and transparent processing solution, and a proprietary split billing solution for this complex market," said Crane. "I am excited to join a growing industry leader and bring value to clients and prospects by using a consultative approach. I look forward to continuing that tradition by providing 340B guidance and insight to our current and future clients."
About RxStrategies, Inc.
Established in 2003 and headquartered in Boca Raton, Florida, RxStrategies, Inc. provides accountability, transparency and value-based solutions for the Federal 340B Drug Pricing Programs. As a full-service 340B Drug Pricing Program services organization, RxStrategies provides a diverse range of services to all “Qualified Entities” and the in-house and/or contract pharmacies, including 340B administration, split billing, orphan drug, and audit services. RxStrategies’ “real-time” comprehensive solutions are designed to meet the challenges of regulatory compliance, patient eligibility, pharmacy replenishment, program tracking and reporting of the Federal 340B Drug Pricing Program. To learn more, please visit www.340Bplus.com.
Media Contact: Cheryl Musial, Media Relations, Mopdog, Inc. [email protected] 678-737-7325


Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 



